Henkel Joins with MedTech Europe to Drive Innovation In the Medical Technology Industry

Henkel, a leading global provider of adhesives, sealants and functional coatings, today announced its membership with MedTech Europe, the industry association representing the medical technology sector in Europe. This collaboration aims to foster innovation and promote sustainable development in the value chains supporting the medical technology industry.

Henkel has a long history of supporting the medical technology industry with its advanced adhesive and surface solutions. Through this, Henkel and MedTech Europe will collaborate on various initiatives such as supporting research and development projects, driving thought leadership and engaging in industry forums. The goal is to accelerate the adoption of innovative solutions, address industry challenges, and contribute to advancing the medical technology sector.

The partnership with MedTech Europe is part of the company’s broader strategy to strengthen its collaborations within the healthcare industry and ecosystem. By collaborating with industry associations, healthcare organizations, and technology providers, Henkel aims to drive innovation and create value for patients, healthcare professionals, and its partners throughout value chains.

“Joining forces with MedTech Europe is an exciting step for us. Together, we will be able to leverage our combined expertise to develop innovative solutions that address the ever-evolving needs of the medical technology industry,” said Dr. Philipp Loosen, Vice President and Head of Industrials EIMEA and Global Key Accounts Medical at Henkel Adhesive Technologies. “MedTech Europe represents the medical technology industry in Europe, covering a wide range of products, including medical devices, diagnostics, imaging equipment, and more.”

Chemical regulatory compliance is important to Henkel, and MedTech Europe provides multiple platforms to collaborate, contribute, and advocate the same through their working groups that deep dive into the aspects of sustainability, chemicals, and medical device regulations. “This is another milestone on our journey to becoming the key player in chemical regulatory compliance for our medical customers that contributes to sustainability and the environment,” said Senthil Pichandi, Vice President Global Product Safety and Regulatory Affairs (PSRA), Henkel Adhesive Technologies.

More here.

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.